Effect of Different Aβ Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid-β40/42 in IVIG

被引:3
作者
Cao, Haijun [1 ]
Du, Xi [1 ]
Zeng, Renyong [1 ]
Lv, Zhaoji [1 ]
Ye, Shengliang [1 ]
Jiang, Peng [1 ]
Wang, Zongkui [1 ]
Ma, Li [1 ]
Huang, Yun [2 ]
Li, Changqing [1 ]
Zhang, Rong [1 ]
Liu, Fengjuan [2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Blood Transfus, 26 Huacai Rd, Chengdu 610052, Sichuan, Peoples R China
[2] Southwest Petr Univ, Sch Mat Sci & Engn, 8 Xindu Rd, Chengdu 610500, Sichuan, Peoples R China
关键词
Naturally occurring autoantibodies against amyloid-beta; intravenous immunoglobulin; Alzheimer's disease; measure; amyloid beta-protein; aggregate; INTRAVENOUS IMMUNOGLOBULIN; ALZHEIMERS-DISEASE; PRECLINICAL MODELS; ANTIBODIES; OLIGOMERS; MONOMER; PEPTIDE; ELISA;
D O I
10.2174/1567205017666200102151731
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The specific Intravenous Immunoglobulin (IVIG) for Alzheimer's Disease (AD) is developing, which contains a high level of naturally occurring autoantibodies against amyloid-beta (nAbs-A beta), and the measure of nAbs-A beta content is greatly essential. Though Enzyme-Linked Immunosorbent Assay (ELISA) has been widely used in detecting the nAbs-A beta content, the impact of A beta aggregates species chosen as antigen in ELISA on this measure has not been evaluated. Objective: To clarify the influence of different A beta(40/42) aggregates as antigen during ELISA on the content of nAbs-A beta(40/42) measured in WIG. Method: Preparation of various A beta(40/42) aggregates was performed by different aggregation solutions and various lengths of time, and analyzed by western blot. Different A beta(40/42) aggregates as antigen were adopted to measure the nAbs-A beta(40/42) content in IVIG by ELISA, and the control was carried out to reduce interference of nonspecific binding. The Bonferroni and Dunnett's T3 were used for statistical analysis. Results: The duration for the formation of A beta(40/42) aggregates had more effect on detecting nAbs-A beta(40/42) content in IVIG than the aggregation solution. Higher content of nAbs-A beta(40/42) in the same IVIG was displayed when measured with A beta(40/42) aggregates at day 3, instead of at day 0.5 and day 7.0. The nAbs-A beta(40/42) contents in the same IVIG measured with A beta(40/42) aggregates prepared in different solutions were obviously different, but there was no significant regularity among them. Conclusion: The nAbs-A beta(40/42) content in the same EVIG is significantly different when measured with A beta(40/42) aggregated under different conditions. The nAbs-A beta(40/42)content in IVIG by antigen-dependent measures, like ELISA, is uncertain.
引用
收藏
页码:1290 / 1299
页数:10
相关论文
共 38 条
[1]   2018 Alzheimer's disease facts and figures [J].
不详 .
ALZHEIMERS & DEMENTIA, 2018, 14 (03) :367-425
[2]   Comparison of Intravenous Immunoglobulins for Naturally Occurring Autoantibodies against Amyloid-β [J].
Balakrishnan, Karthikeyan ;
Andrei-Selmer, Luminita-Cornelia ;
Selmer, Thorsten ;
Bacher, Michael ;
Dodel, Richard .
JOURNAL OF ALZHEIMERS DISEASE, 2010, 20 (01) :135-143
[3]   Globular amyloid β-peptide1-42 oligomer -: a homogenous and stable neuropathological protein in Alzheimer's disease [J].
Barghorn, S ;
Nimmrich, V ;
Striebinger, A ;
Krantz, C ;
Keller, P ;
Janson, B ;
Bahr, M ;
Schmidt, M ;
Bitner, RS ;
Harlan, J ;
Barlow, E ;
Ebert, U ;
Hillen, H .
JOURNAL OF NEUROCHEMISTRY, 2005, 95 (03) :834-847
[4]   The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes [J].
Benilova, Iryna ;
Karran, Eric ;
De Strooper, Bart .
NATURE NEUROSCIENCE, 2012, 15 (03) :349-357
[5]   Forecasting the global burden of Alzheimer's disease [J].
Brookmeyer, Ron ;
Johnson, Elizabeth ;
Ziegler-Graham, Kathryn ;
Arrighi, H. Michael .
ALZHEIMERS & DEMENTIA, 2007, 3 (03) :186-191
[6]   Overview of Immunotherapy in Alzheimer's Disease (AD) and Mechanisms of IVIG Neuroprotection in Preclinical Models of AD [J].
Counts, Scott E. ;
Lahiri, Debomoy K. .
CURRENT ALZHEIMER RESEARCH, 2014, 11 (07) :623-625
[7]   Intravenous Immunoglobulin (IVIG) Treatment Exerts Antioxidant and Neuropreservatory Effects in Preclinical Models of Alzheimer's Disease [J].
Counts, Scott E. ;
Ray, Balmiki ;
Mufson, Elliott J. ;
Perez, Sylvia E. ;
He, Bin ;
Lahiri, Debomoy K. .
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 :S80-S85
[8]  
Cummings Jeffrey, 2018, Alzheimers Dement (N Y), V4, P195, DOI 10.1016/j.trci.2018.03.009
[9]  
Cummings Jeffrey, 2017, Alzheimers Dement (N Y), V3, P367, DOI 10.1016/j.trci.2017.05.002
[10]   Human antibodies against amyloid β peptide:: A potential treatment for Alzheimer's disease [J].
Dodel, R ;
Hampel, H ;
Depboylu, C ;
Lin, SZ ;
Gao, F ;
Shock, S ;
Jäckel, S ;
Wei, W ;
Buerger, K ;
Höft, C ;
Hemmer, B ;
Möller, HJ ;
Farlow, M ;
Oertel, WH ;
Sommer, N ;
Du, YS .
ANNALS OF NEUROLOGY, 2002, 52 (02) :253-256